An 80‑gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis

Empuku,Shinichiro; Nakajima,Kentaro; Akagi,Tomonori; Kaneko,Kunihiko; Hijiya,Naoki; Etoh,Tsuyoshi; Shiraishi,Norio; Moriyama,Masatsugu; Inomata,Masafumi

doi:10.3892/mco.2016.806

An 80‑gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis

Authors:
- Shinichiro Empuku
- Kentaro Nakajima
- Tomonori Akagi
- Kunihiko Kaneko
- Naoki Hijiya
- Tsuyoshi Etoh
- Norio Shiraishi
- Masatsugu Moriyama
- Masafumi Inomata
View Affiliations

Affiliations: Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Oita 879‑5593, Japan, Department of Computer Science, Fukuyama University Faculty of Engineering, Fukuyama, Hiroshima 720‑0292, Japan, Department of Molecular Pathology, Oita University Faculty of Medicine, Yufu, Oita 879‑5593, Japan, Center for Community Medicine, Oita University Faculty of Medicine, Yufu, Oita 879‑5593, Japan
Published online on: March 7, 2016 https://doi.org/10.3892/mco.2016.806
Pages: 733-739

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preoperative chemoradiotherapy (crt) for locally advanced rectal cancer not only improves the postoperative local control rate, but also induces downstaging. However, it has not been established how to individually select patients who receive effective preoperative CRT. The aim of this study was to identify a predictor of response to preoperative CRT for locally advanced rectal cancer. This study is additional to our multicenter phase II study evaluating the safety and efficacy of preoperative CRT using oral fluorouracil (UMIN ID: 03396). From April, 2009 to August, 2011, 26 biopsy specimens obtained prior to CRT were analyzed by cyclopedic microarray analysis. Response to CRT was evaluated according to a histological grading system using surgically resected specimens. To decide on the number of genes for dividing into responder and non‑responder groups, we statistically analyzed the data using a dimension reduction method, a principle component analysis. Of the 26 cases, 11 were responders and 15 non‑responders. No significant difference was found in clinical background data between the two groups. We determined that the optimal number of genes for the prediction of response was 80 of 40,000 and the functions of these genes were analyzed. When comparing non‑responders with responders, genes expressed at a high level functioned in alternative splicing, whereas those expressed at a low level functioned in the septin complex. Thus, an 80‑gene expression set that predicts response to preoperative CRT for locally advanced rectal cancer was identified using a novel statistical method.

View Figures

View References

1	Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P and Krieg RM: Timing of Rectal Cancer Response to Chemoradiation Consortium: Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 254:97–102. 2011. View Article : Google Scholar : PubMed/NCBI
2	Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B and van de Velde CJ: Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet. 12:575–582. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC: EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
5	Martling A, Holm T, Johansson H, Rutqvist LE and Cedermark B: Stockholm Colorectal Cancer Study Group: The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: Long-term follow-up of a population-based study. Cancer. 92:896–902. 2001. View Article : Google Scholar : PubMed/NCBI
6	Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, et al: Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study. Lancet Oncol. 15:184–190. 2014. View Article : Google Scholar : PubMed/NCBI
7	Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
8	Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, et al: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicenter, randomised trial. Lancet. 373:811–820. 2009. View Article : Google Scholar : PubMed/NCBI
9	Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
10	Murata A, Yoshida K, Maeda K, et al: A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ASCO abstract. #3515:2015.
11	Nakamura T, Yamashita K, Sato T, Ema A, Naito M and Watanabe M: Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: Impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys. 89:547–555. 2014. View Article : Google Scholar : PubMed/NCBI
12	Inomata M, Akagi T, Nakajima K, Etoh T, Shiraishi N, Tahara K, Matsumoto T, Kinoshita T, Fujii K, Shiromizu A, et al: A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial. Mol Clin Oncol. 4:510–514. 2016.
13	Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, Marcet J and Pastor C: Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 254:486–493; discussion 492–493. 2011. View Article : Google Scholar : PubMed/NCBI
14	Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Konishi T, Horie H, Ikeuchi H, et al: Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol. 13:419–425. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J and Miyatani T: Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genomics Proteomics. 8:87–92. 2011.PubMed/NCBI
16	Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Oba K and Watanabe T: Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol. 13:302015. View Article : Google Scholar : PubMed/NCBI
17	Spitzner M, Emons G, Kramer F, Gaedcke J, Rave-Fränk M, Scharf JG, Burfeind P, Becker H, Beissbarth T, Ghadimi BM, et al: A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys. 78:1184–1192. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell. Hoboken: 2009.
19	Japanese Society for Cancer of the Colon and Rectum: Japanese Classification of Colorectal Carcinoma (2nd English). Kanehara Shuppan Co. Ltd. Japan: 2009.
20	Quackenbush J: Microarray data normalization and transformation. Nat Genet. 32(Suppl): 496–501. 2002. View Article : Google Scholar : PubMed/NCBI
21	Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 29:365–371. 2001. View Article : Google Scholar : PubMed/NCBI
22	da Huang W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
23	da Huang W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
24	Rousseeuw PJ: Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. Comput Appl Math. 20:53–65. 1987. View Article : Google Scholar
25	Nishino S, Itoh A, Matsuoka H, Maeda K and Kamoshida S: Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy. Mol Clin Oncol. 1:661–667. 2013.PubMed/NCBI
26	Pal S, Gupta R and Davuluri RV: Alternative transcription and alternative splicing in cancer. Pharmacol Ther. 136:283–294. 2012. View Article : Google Scholar : PubMed/NCBI
27	Haley J and White FM: Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance. Biochem Soc Trans. 42:758–764. 2014. View Article : Google Scholar : PubMed/NCBI
28	Cutillas PR: Role of phosphoproteomics in the development of personalized cancer therapies. Proteomics Clin Appl. 9:383–395. 2015. View Article : Google Scholar : PubMed/NCBI
29	Mostowy S and Cossart P: Septins: The fourth component of the cytoskeleton. Nat Rev Mol Cell Biol. 13:183–194. 2012.PubMed/NCBI
30	Connolly D, Abdesselam I, Verdier-Pinard P and Montagna C: Septin roles in tumorigenesis. Biol Chem. 392:725–738. 2011. View Article : Google Scholar : PubMed/NCBI